Dr. Corey Langer Discusses Erlotinib in Advanced Non-Small Cell Lung Cancer

0 Views
administrator
administrator
07/14/23

Corey J. Langer, MD, Professor of Medicine, Hematology/Oncology Division, University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib (Tarceva) for patients with non-small cell lung cancer (NSCLC).

For more resources on lung cancer, visit http://www.onclive.com/specialty/lung-cancer

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next